Syntis Bio

Syntis Bio is a clinical-stage biopharmaceutical company with the mission of developing oral therapies to provide more accessible, effective, and sustainable solutions across healthcare areas ranging from rare genetic diseases to some of the world’s most common conditions. By leveraging the unique biology of the small intestine as a nexus for metabolic control, digestion, and drug absorption, the company is rapidly advancing a pipeline of programs addressing metabolic diseases, from obesity to rare pediatric indications such as Homocystinuria (HCU) and Maple Syrup Urine Disease (MSUD).